Tumor profiling in pancreatic carcinoma, a multidisciplinary initiative
Completed
- Conditions
- pancreatic cancerpancreatic carcinoma10017990
- Registration Number
- NL-OMON35953
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
Suspicion of potentially resectable and irresectable pancreatic malignancy on preoperative imaging
Exclusion Criteria
Not able to give informed consent
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The expression of stem cell markers in cell cultures and xenograft models,<br /><br>serum protein markers, and DNA/RNA profiles, will be correlated to<br /><br>clinicopathological characteristics like survival and TNM classification.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Amount of viable tumor cells in biopsies taken at the OR/Pathology (quality<br /><br>comparison).<br /><br>Optimal procedures for processing of the tissues (we follow standard operating<br /><br>procedures in the laboratories).</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular subtypes of pancreatic ductal adenocarcinoma are identified in the NL-OMON35953 tumor profiling study?
How does tumor mutational burden profiling in NL-OMON35953 compare to standard-of-care treatment outcomes in pancreatic cancer?
Which biomarkers in the Pancreas bio bank project predict response to immune checkpoint inhibitors in pancreatic carcinoma?
What adverse events are associated with non-invasive tumor profiling techniques in the NL-OMON35953 trial?
How do KRAS and TP53 mutations in NL-OMON35953 influence targeted therapy development for pancreatic cancer?